#1 Clinical Trials Search in Europe

Vonicog Alfa

Vonicog Alfa, a recombinant von Willebrand factor (rVWF), is being studied in clinical trials as a potential treatment for severe von Willebrand Disease (VWD) in children. These trials aim to evaluate the efficacy, safety, and tolerability of Vonicog Alfa in controlling bleeding episodes and preventing bleeding in pediatric patients with this rare blood clotting disorder. The studies focus on both on-demand treatment and prophylactic use of the drug, offering hope for improved management of VWD in young patients.

Table of Contents

What is Vonicog Alfa?

Vonicog alfa, also known by its brand name VEYVONDI, is a medication used to treat a bleeding disorder called von Willebrand Disease (VWD). It is specifically designed for children with severe VWD who need help controlling bleeding episodes or who are undergoing surgery.[1]

Vonicog alfa is a recombinant human von Willebrand factor, which means it’s an artificial version of a protein that helps blood clot. It’s made in a laboratory using advanced genetic techniques, rather than being derived from human blood.[2]

What is von Willebrand Disease?

Von Willebrand Disease (VWD) is an inherited bleeding disorder. People with VWD have a problem with a protein in their blood called von Willebrand factor, which helps blood clot. When you have VWD, your blood doesn’t clot properly, which can lead to excessive bleeding.[1]

There are different types of VWD, ranging from mild to severe. The severe form, which vonicog alfa is designed to treat, can cause serious bleeding problems that may require medical treatment.[1]

How Vonicog Alfa Works

Vonicog alfa works by replacing the missing or defective von Willebrand factor in the blood of people with VWD. This helps the blood to clot properly, reducing the risk of excessive bleeding.[2]

In some cases, vonicog alfa may be used along with another medication called octocog alfa (ADVATE), which replaces another clotting factor (Factor VIII) that may also be low in some people with VWD.[1]

Clinical Studies on Vonicog Alfa

Researchers are conducting clinical trials to study how well vonicog alfa works in children with severe VWD. These studies are looking at several important aspects:

  • How effective vonicog alfa is in controlling bleeding episodes[1]
  • How safe it is to use in children<a href="#1][2]
  • How well it works to prevent bleeding in children who take it regularly (called prophylaxis)[2]
  • How the body processes the medication (pharmacokinetics)[1][2]

These studies are focusing on children under 18 years old with severe VWD who have needed treatment with VWF products in the past.[1][2]

How Vonicog Alfa is Administered

Vonicog alfa is given as an intravenous injection, which means it’s injected directly into a vein. It comes in two strengths: 650 IU and 1300 IU (IU stands for International Units, a standard measure for many medications).[1][2]

The dose and frequency of treatment depend on several factors, including the severity of the VWD, the type of bleeding, and the individual patient’s needs. In some cases, it may be given regularly to prevent bleeding (prophylaxis), while in other cases it might be used only when bleeding occurs or before surgery.[2]

Safety and Side Effects

As with any medication, vonicog alfa can potentially cause side effects. The clinical trials are carefully monitoring for any adverse events, including:

  • Allergic reactions[1][2]
  • Development of antibodies against the medication[1][2]
  • Blood clots (thrombotic events)[1][2]
  • Any other unexpected side effects[1][2]

It’s important to note that the medication is still being studied in children, and the full safety profile is not yet known. Parents and caregivers should discuss potential risks and benefits with their healthcare provider.[1][2]

Conclusion

Vonicog alfa (VEYVONDI) represents an important advancement in the treatment of severe von Willebrand Disease in children. By replacing the missing clotting factor, it aims to help control and prevent bleeding episodes, potentially improving quality of life for children with this condition. As clinical trials progress, we will learn more about its effectiveness and safety in pediatric patients.[1][2]

If your child has been diagnosed with severe VWD, talk to your healthcare provider about whether vonicog alfa might be an appropriate treatment option.

Aspect Details
Drug Name Vonicog Alfa (recombinant von Willebrand factor)
Condition Studied Severe von Willebrand Disease in children
Age Group Children under 18 years old
Main Objectives Evaluate efficacy, safety, and tolerability in controlling and preventing bleeding episodes
Treatment Types On-demand treatment and prophylaxis
Primary Outcome Measures Hemostatic efficacy, Annualized Bleeding Rate (ABR)
Safety Monitoring Adverse events, thrombotic events, hypersensitivity reactions, antibody development
Additional Assessments Pharmacokinetics, Pharmacodynamics, Quality of Life

FAQ

  • What is Vonicog Alfa? Vonicog Alfa is a recombinant von Willebrand factor (rVWF) being studied as a treatment for severe von Willebrand Disease. It is designed to replace the missing or defective von Willebrand factor in patients with this blood clotting disorder.
  • What age group is being studied in these clinical trials? The clinical trials are focusing on children under 18 years of age with severe von Willebrand Disease. One study specifically includes children from birth to less than 18 years old at the time of screening.
  • What are the main objectives of these clinical trials? The main objectives are to evaluate the efficacy, safety, and tolerability of Vonicog Alfa in controlling bleeding episodes, assess its use in surgical procedures, and study its effectiveness as a prophylactic treatment to prevent bleeding in children with severe VWD.
  • How is the effectiveness of Vonicog Alfa measured in these trials? Effectiveness is primarily measured by the hemostatic efficacy, which includes the success rate in treating bleeding episodes, the number of infusions required, and the annualized bleeding rate (ABR) during prophylactic treatment compared to historical data.
  • What safety aspects are being monitored in these trials? The trials are monitoring for adverse events, including thrombotic events, severe hypersensitivity reactions, and the development of antibodies to VWF and FVIII. They also assess vital signs and clinical laboratory parameters to ensure the overall safety of Vonicog Alfa in pediatric patients.

Ongoing Clinical Trials on Vonicog Alfa

  • Study on the Safety and Effectiveness of Emicizumab for Patients with Type 3 Von Willebrand Disease

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +2

  • Study on Preventing Bleeding in Children with Severe von Willebrand Disease Using Vonicog Alfa and Octocog Alfa

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Ireland Italy Spain

  • Study on the Effectiveness and Safety of Vonicog Alfa with or without Octocog Alfa for Children with Severe von Willebrand Disease Experiencing Bleeding or Undergoing Surgery

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium France Italy Spain

Glossary

  • Von Willebrand Disease (VWD): A genetic bleeding disorder caused by missing or defective von Willebrand factor (VWF), a blood clotting protein.
  • Vonicog Alfa: A recombinant von Willebrand factor (rVWF) being studied as a treatment for severe von Willebrand Disease.
  • Hemostatic Efficacy: The effectiveness of a treatment in stopping or controlling bleeding.
  • Annualized Bleeding Rate (ABR): The number of bleeding episodes a patient experiences in a year, used to measure the effectiveness of prophylactic treatment.
  • Prophylaxis: Regular treatment given to prevent bleeding episodes in patients with bleeding disorders.
  • Recombinant: Produced using genetic engineering techniques, as opposed to being derived from human or animal sources.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body.
  • Inhibitor: An antibody that neutralizes the effect of a clotting factor, potentially reducing the effectiveness of treatment.
  • Thrombotic Event: The formation of a blood clot in a blood vessel, which can be a potential side effect of some treatments for bleeding disorders.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-vonicog-alfa-with-or-without-octocog-alfa-for-children-with-severe-von-willebrand-disease-experiencing-bleeding-or-undergoing-surgery/
  2. http://clinicaltrials.eu/trial/study-on-preventing-bleeding-in-children-with-severe-von-willebrand-disease-using-vonicog-alfa-and-octocog-alfa/